US Patent 9,572,797: Tetrahydrocannabinol Derivatives as Cannabinoid Receptor Modulators
United States Patent 9,572,797, granted on February 21, 2017, to S.A. Biomedical Research, Inc., claims a class of tetrahydrocannabinol (THC) derivatives designed to act as cannabinoid receptor modulators. The patent focuses on compounds that can selectively bind to either the CB1 or CB2 cannabinoid receptors, or both, offering potential therapeutic applications in pain management, inflammation, neurological disorders, and metabolic diseases. The claims encompass specific chemical structures, pharmaceutical compositions containing these compounds, and methods of treating various conditions. The patent landscape reveals ongoing research in cannabinoid receptor modulation, with this patent contributing a specific structural class and therapeutic indications.
What are the core chemical structures claimed in US Patent 9,572,797?
The patent claims a general formula for tetrahydrocannabinol derivatives and specific exemplified compounds. The core structure is a modification of the classical THC molecule.
The general formula provided in the patent is:
R1 is selected from hydrogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -CH2-O-R7;
R2 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -O-R7;
R3 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -O-R7;
R4 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -O-R7;
R5 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -O-R7;
R6 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or -O-R7;
R7 is selected from alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, acyl, or a protecting group;
where at least one of R1, R2, R3, R4, R5, or R6 is a substituent other than hydrogen or methyl.
The patent further defines specific positions and types of substituents that can be attached to the core THC scaffold, including variations at the C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, and C13 positions. Crucially, the substituents are designed to influence the binding affinity and selectivity for CB1 and CB2 receptors.
Key exemplified compounds include:
- Compound 10: A specific THC derivative with defined substituents at various positions.
- Compound 11: Another example illustrating the structural variations covered.
- Compound 12: Further illustrating the scope of the claimed chemical space.
- Compound 13: A representative structure demonstrating the patent's scope.
- Compound 14: An additional example of the claimed chemical entities.
These examples provide concrete instances of the broader chemical genus protected by the patent, allowing for a more precise understanding of the patented technology.
What are the claimed therapeutic uses and methods of treatment?
US Patent 9,572,797 asserts that the claimed THC derivatives can be used to treat a range of medical conditions by modulating cannabinoid receptors. The patent details methods of treatment involving the administration of a therapeutically effective amount of the claimed compounds.
The patent claims methods of treating:
- Pain: Including neuropathic pain, inflammatory pain, and nociceptive pain. The modulation of CB1 receptors is often associated with analgesia.
- Inflammatory Conditions: Such as arthritis, inflammatory bowel disease, and psoriasis. CB2 receptor activation is known to exert anti-inflammatory effects.
- Neurological Disorders: Including epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease, and anxiety disorders. Cannabinoid receptor modulation can influence neurotransmission and neuroprotection.
- Metabolic Diseases: Such as obesity and diabetes. Cannabinoid receptors play a role in regulating appetite, energy balance, and glucose metabolism.
- Ophthalmic Diseases: Including glaucoma.
- Cardiovascular Diseases: Including atherosclerosis and hypertension.
- Cancer: Potentially through anti-proliferative or pro-apoptotic effects, or by managing symptoms like nausea and pain.
The methods involve administering the compounds orally, topically, transdermally, intravenously, intramuscularly, or by inhalation. The patent specifies the formulation of pharmaceutical compositions, which can include excipients, diluents, and carriers suitable for the chosen route of administration.
How does US Patent 9,572,797 relate to existing cannabinoid research and development?
US Patent 9,572,797 contributes to the substantial body of intellectual property and scientific literature surrounding cannabinoid receptor modulators. The patent's focus on THC derivatives with defined selectivity for CB1 or CB2 receptors distinguishes it within this field.
The broader landscape includes:
- Endocannabinoid System (ECS) Research: The patent is grounded in the understanding of the ECS, which comprises cannabinoid receptors (CB1 and CB2), endogenous cannabinoids (endocannabinoids), and enzymes that synthesize and degrade endocannabinoids.
- Synthetic Cannabinoids: A significant portion of research has focused on synthetic cannabinoids, both full agonists and antagonists, targeting various aspects of ECS function. This patent claims a specific class of these synthetic molecules.
- Pharmaceutical Development: Numerous companies and research institutions are actively developing cannabinoid-based therapeutics. Some focus on naturally derived cannabinoids (like CBD and THC from cannabis plants), while others develop synthetic analogs to achieve specific pharmacological profiles and avoid regulatory challenges associated with plant-derived cannabis.
- Selectivity of Receptor Binding: A key area of interest in cannabinoid research is achieving selectivity for CB1 or CB2 receptors. CB1 receptor activation is associated with psychoactive effects and is a target for pain and appetite control, but also potential side effects. CB2 receptor activation is primarily linked to immunomodulatory and anti-inflammatory effects with less psychoactivity. This patent aims to exploit these distinctions.
- Patents on Cannabinoid Analogs: The patent literature is rich with patents claiming various synthetic cannabinoid structures and their therapeutic applications. For example, other patents may cover different classes of CB1 antagonists for obesity (like Rimonabant, though later withdrawn), or CB2 agonists for inflammatory conditions.
US Patent 9,572,797 carves out a specific niche by claiming a particular structural framework derived from THC, offering a new set of chemical entities with potentially unique pharmacological properties for modulation of the ECS.
What is the patent landscape surrounding cannabinoid receptor modulators?
The patent landscape for cannabinoid receptor modulators is extensive and competitive, reflecting significant commercial and therapeutic interest. US Patent 9,572,797 exists within this dynamic environment.
Key aspects of the patent landscape include:
- Broad Claims on Receptor Activity: Many early patents covered broad classes of compounds that showed activity at cannabinoid receptors.
- Focus on Selectivity: As research has progressed, there has been a shift towards patents claiming compounds with specific selectivity for CB1 or CB2 receptors, or for particular signaling pathways downstream of receptor activation. This patent aligns with this trend by aiming for selective modulation.
- Therapeutic Indications: Patents often claim novel compounds in conjunction with specific therapeutic uses. This patent covers a wide array of indications, from pain and inflammation to neurological and metabolic disorders.
- Composition of Matter Claims: The strongest patent protection is typically granted for novel chemical entities (composition of matter claims), which are the primary claims in US Patent 9,572,797.
- Method of Treatment Claims: Claims covering methods of using existing or novel compounds to treat specific diseases are also common and important for commercialization.
- Exclusivity for Natural Products: Patents also exist for extraction, purification, and specific formulations of naturally occurring cannabinoids like CBD and THC.
- Key Players: Major pharmaceutical companies, specialized biotechnology firms, and academic institutions are all active in patenting cannabinoid-related inventions.
The competitive nature of this landscape means that companies seeking to develop or invest in cannabinoid therapeutics must conduct thorough freedom-to-operate analyses to navigate existing intellectual property and identify opportunities for innovation. US Patent 9,572,797 represents one such piece of intellectual property within this complex domain.
What are the potential business implications of US Patent 9,572,797?
The existence and claims of US Patent 9,572,797 have several potential business implications for companies involved in drug discovery, development, and investment within the cannabinoid therapeutic space.
For Competitors:
- Freedom-to-Operate (FTO) Challenges: Companies developing THC derivatives or other cannabinoid receptor modulators with similar structural features or therapeutic targets must conduct FTO analyses to determine if their activities infringe on this patent.
- Licensing Opportunities: If a company's development pipeline intersects with the claims of US Patent 9,572,797, they may need to seek a license from S.A. Biomedical Research, Inc. This could involve upfront payments, milestone payments, and royalties.
- Strategic Partnerships: S.A. Biomedical Research, Inc. could potentially partner with larger pharmaceutical companies for further development and commercialization of its patented compounds.
For Investors:
- Due Diligence: Investors in companies operating in the cannabinoid therapeutic sector should assess the patent portfolios of target companies, including identifying any patents that could pose a risk or offer an advantage. US Patent 9,572,797 would be a factor in such due diligence.
- Valuation of IP: The strength and scope of a patent, like 9,572,797, contribute to the valuation of the patent holder's assets and potential future revenue streams.
- Market Segmentation: Understanding which chemical classes and therapeutic targets are patented can help investors identify areas of the market that are more or less crowded with intellectual property.
For S.A. Biomedical Research, Inc.:
- Monopoly Power: The patent grants S.A. Biomedical Research, Inc. exclusive rights to make, use, sell, and import the claimed compounds and methods in the United States for a period of 20 years from the filing date (with potential extensions). This provides a significant competitive advantage.
- Revenue Generation: The patent can be leveraged through direct commercialization of its own products, licensing agreements with other entities, or through sale of the patent itself.
- Foundation for Further R&D: The patent can serve as a foundational asset upon which further research and development into improved analogs, formulations, or new therapeutic applications can be built.
The duration of patent protection is critical. US Patent 9,572,797 was filed on October 13, 2015, and granted on February 21, 2017. Its term extends 20 years from the filing date, meaning it will expire in October 2035, subject to any potential patent term extensions.
Key Takeaways
- US Patent 9,572,797 claims novel tetrahydrocannabinol (THC) derivatives designed as cannabinoid receptor modulators.
- The patent encompasses specific chemical structures and pharmaceutical compositions containing these compounds.
- Claimed therapeutic uses include treatment of pain, inflammation, neurological disorders, and metabolic diseases.
- The patent operates within a competitive landscape of cannabinoid research, contributing specific chemical entities and therapeutic targets.
- Business implications include potential freedom-to-operate challenges for competitors, licensing opportunities, and considerations for investor due diligence.
Frequently Asked Questions
What is the expiration date of US Patent 9,572,797?
The patent was filed on October 13, 2015, and has a term of 20 years from the filing date, meaning it is set to expire in October 2035, barring any patent term extensions.
Does this patent cover naturally occurring THC?
No, US Patent 9,572,797 specifically claims synthetic derivatives of THC, which are chemically modified structures, not naturally occurring THC itself.
Can other companies develop cannabinoid drugs while this patent is in force?
Other companies can develop cannabinoid drugs, but they must ensure their compounds and methods do not infringe on the specific claims of US Patent 9,572,797. This requires a thorough freedom-to-operate analysis.
What is the primary mechanism of action for the claimed compounds?
The claimed compounds are designed to modulate cannabinoid receptors, specifically CB1 and CB2 receptors, by binding to them.
Does the patent claim a cure for any disease?
The patent claims methods of treating various diseases, not a definitive cure. Treatment implies management or amelioration of symptoms and conditions.
Citations
[1] S.A. Biomedical Research, Inc. (2017). Tetrahydrocannabinol derivatives as cannabinoid receptor modulators. U.S. Patent 9,572,797. Retrieved from USPTO database.
